Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Tripterygium wilfordii Hook F Treatment for Idiopathic Refractory Nephrotic Syndrome in Adults: A Meta-Analysis

Xu G.a, b · Tu W.a · Jiang D.b · Xu C.a

Author affiliations

aDepartment of Nephrology, Second Affiliated Hospital, Nanchang University, Nanchang, and bDepartment of Immunology, Shangrao Branch of Jiangxi Medical College, Shangrao, PR China

Related Articles for ""

Nephron Clin Pract 2009;111:c223

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: August 29, 2008
Accepted: October 03, 2008
Published online: March 14, 2009
Issue release date: May 2009

Number of Print Pages: 1
Number of Figures: 5
Number of Tables: 1


eISSN: 1660-2110 (Online)

For additional information: https://www.karger.com/NEC

Abstract

Tripterygium wilfordii Hook F (TwHF) is a Chinese herbal medicine with immunosuppressive effects and an established history of use in the treatment of inflammatory and autoimmune diseases. We have carried out a meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs which assessed the effectiveness of TwHF in the treatment for idiopathic refractory nephrotic syndrome (IRNS). After reading the full text, only three RCTs or quasi-RCTs meeting our inclusion criteria were selected. Our meta-analysis indicated that TwHF has beneficial effects on the remission of IRNS. There was no significant publication bias in the meta-analysis studies. However, studies with a larger sample size and including patients with both a mild and severe histopathological change involvement separately are needed to assess the effects of TwHF in IRNS patients before exact conclusions can be drawn.

© 2009 S. Karger AG, Basel


References

  1. Chang DM, Chang WY, Kuo SY, Chang ML: The effects of traditional antirheumatic herbal medicines on immune response cells. J Rheumatol 1997;24:436–441.
  2. Wong KF, Chan JK, Chan KL, Tam P, Yang D, Fan ST, Luk JM: Immunochemical characterization of the functional constituents of Tripterygium wilfordii contributing to its anti-inflammatory property. Clin Exp Pharmacol Physiol 2008;35:55–59.
  3. Ji SM, Wang QW, Chen JS, Sha GZ, Liu ZH, Li LS: Clinical trial of Tripterygium wilfordii Hook F in human kidney transplantation in China. Transplant Proc 2006;38:1274–1279.
  4. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
  5. He JY: Combined leflunomide and Tripterygium wilfordii with prednisone to treat idiopathic refractory nephrotic syndrome. Chin J Nephrol 2007;23:206.
  6. Zhong ZH, Lu JJ, Cai CD: Clinical analysis of Prednisone and Tripterygium wilfordii treatment for relapsing nephrotic syndrome. Clin Med Chin 2002;18:435–436.
  7. Xiao HQ, Ding GH, Zhang JE, Zhang QH, Li T, Luo CX: Comparison between Tripterygium wilfordii and cyclophosphamide treatment for idiopathic refractory nephrotic syndrome. Clin Focus 2003;18:1039–1040.
  8. Patavino T, Brady DM: Natural medicine and nutritional therapy as an alternative treatment in systemic lupus erythematosus. Altern Med Rev 2001;6:460–471.
  9. Ioannidis JP: Genetic associations: false or true? Trends Mol Med 2003;9:135–138.
  10. Lee YH, Harley JB, Nath SK: CTLA-4 polymorphisms and systemic lupus erythematosus: a meta-analysis. Hum Genet 2005;116:361–367.
  11. Wang XD, Gao WY, Yao Z, Zhang SY, Zhang YW, Takaishi Y, Duan HQ: Immunosuppressive sesquiterpenes from Tripterygium wilfordii. Chem Pharm Bull 2005;53:607–610.
  12. Tao X, Sun Y, Dong Y, et al: A prospective, controlled, double-blind, crossover study of Tripterygium Wilfordii Hook F in the treatment of rheumatoid arthritis. Chin Med J Engl 1989;102:327–331.
  13. Gu WZ, Brandwein SR: Inhibition of type II collagen induced arthritis in rats by triptolide. Int J Immunopharmacol 1998;20:389–400.
  14. Zheng J, Gu K, Xu L, Gao J, Yu Y, Tang M: Screening of active anti-inflammatory, immunosuppressive and antifertility components of Tripterygium wilfordii. III. A comparison of the anti-inflammatory and immunosuppressive activities of 7 diterpene lactone epoxide compounds in vivo. Acta Acad Med Sin 1991;13:391–397.
  15. Zheng J, Feng K, Gu K: Screening of active anti-inflammatory, immunosuppressive and antifertility components of Tripterygium wilfordii V. Effects of 7 diterpene lactone epoxide compounds on the proliferation of T and B lymphocytes in vitro. Acta Acad Med Sin 1994;16:24–28.
  16. Wang B, Ma L, Tao X, Lipsky PE: Triptolide, an active component of the Chinese herbal remedy Tripterygium wilfordii Hook F, inhibits production of nitric oxide by decreasing inducible nitric oxide synthase. Arthritis Rheum 2004;50:2995–3003.
  17. Hong Y, Zhou W, Li K, Sacks SH: Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells. Kidney Int 2002;62:1291–1300.
  18. Krishna G, Liu K, Shigemitsu H: PG-490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Am J Pathol 2001;158:997–1004.
  19. Tao X, Cush JJ, Garret M, Lipsky PE: A phase I study of ethyl acetate extract of the Chinese antirheumatic herb Tripterygium wilfordii Hook F in rheumatoid arthritis. J Rheumatol 2001;28:2160–2167.
  20. Tao X, Lipsky PE: The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 2000;26:29–50.
  21. Chen JR, Yen JH, Lin CC, et al: The effects of Chinese herbs on improving survival and inhibiting anti-dsDNA antibody production in lupus mice. Am J Chin Med 1993;21:257–262.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: August 29, 2008
Accepted: October 03, 2008
Published online: March 14, 2009
Issue release date: May 2009

Number of Print Pages: 1
Number of Figures: 5
Number of Tables: 1


eISSN: 1660-2110 (Online)

For additional information: https://www.karger.com/NEC


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.